Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WINDWARD: Mirivadelgat in PH-ILD
NCT06475781Phase 2Recruiting
- Sponsor
- Foresee Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of mirivadelgat in Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD), sponsored by Foresee Pharmaceuticals. Started Mar 2025; status: recruiting.
02
Drugs
mirivadelgat
03
Conditions
Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT06475781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475781.